AssetMark Inc’s ImmunityBio IBRX Stock Holding History

AssetMark Inc’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$8	–	3607
2026 Q1	$8	Buy	+1	New	+$7	﹤0.01%	3429
2025 Q4	–	Sell	-48	Closed	-$118	–	3421
2025 Q3	$118	Hold	48	–	–	﹤0.01%	3108
2025 Q2	$127	Buy	+48	New	+$129	﹤0.01%	2923

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AssetMark Inc's IBRX Position: Q2 2026 in Review

AssetMark Inc sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 1 share — an estimated $8 sold.

AssetMark Inc first reported a position in IBRX in Q2 2025 and held it in 3 quarters. The position peaked at $127 in Q2 2025. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

AssetMark Inc reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
AssetMark Inc sold 1 ImmunityBio share in Q2 2026, an estimated $8.
AssetMark Inc first reported a position in ImmunityBio in Q2 2025 and held it in 3 quarters.
AssetMark Inc's ImmunityBio position peaked at $127 in Q2 2025.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.